Shareholders of Arvaya Healthcare Limited have approved a slate of strategic and administrative resolutions through a postal ballot process that concluded on August 13, 2026. The most significant outcome was the approval of the acquisition of Sushodha Institute of Gastroenterology Private Limited, executed through a preferential issue of equity shares for consideration other than cash.

The company, formerly known as Bijoy Hans Limited, also secured shareholder consent to shift its registered office from Assam to Maharashtra and to regularize the appointment of Mr. Bidari Kotresh Anilkumar as Executive Director. All six resolutions on the ballot were passed with unanimous support from those who voted.

Voting Breakdown and Resolution Details

The postal ballot was scrutinized by Mr. Chinmay Mohan Lele, a Company Secretary, whose report was issued on August 14, 2026. As of the record date of July 10, 2026, the company had 3,416 shareholders. The total outstanding shares stood at 48,021,857.

Voting participation varied across resolutions. For the acquisition-related resolutions, public non-institutional shareholders polled 51.19% of their held shares. In contrast, participation for the name change and registered office shift resolutions was higher at 56.35% among the same group. Promoter and promoter group entities, holding 14,703,679 shares, voted in full (100%) on all resolutions except the related-party transaction, where they abstained as required.

What the Numbers Show

A key structural observation from the voting data is the complete abstention of promoter group votes on the special resolution concerning the acquisition of Sushodha Institute of Gastroenterology Private Limited. While promoters hold 14,703,679 shares, they cast zero votes on this specific agenda item, likely due to conflict of interest rules given their declared interest in the related-party transaction. Consequently, the entire burden of approval fell on public non-institutional shareholders, who voted 17,054,742 shares in favor with zero votes against. This indicates strong minority shareholder support for the deal despite the promoters' recusal.

Additionally, no institutional investors participated in the voting, as the "Public-Institutions" category showed zero shares held and zero votes polled across all resolutions. This suggests the company's institutional investor base may be minimal or entirely absent from the register as of the record date.

Arvaya Healthcare Limited (formerly Bijoy Hans Limited) reported a return to profitability on a consolidated basis for the first quarter ended June 30, 2026, driven by a sharp expansion in revenue. The company posted a consolidated net profit after tax of ₹53.23 lakh, a significant improvement from the net loss of ₹25.29 lakh recorded in the corresponding quarter of FY25.

Consolidated revenue from operations more than tripled to ₹2,990.67 lakh in Q1FY27, up from ₹911.33 lakh in Q1FY26. This top-line growth outpaced the preceding quarter’s revenue of ₹911.33 lakh, indicating accelerated business activity in the current period. The Board of Directors approved the unaudited financial results in a meeting held on August 12, 2026.

Consolidated vs Standalone Performance

While the consolidated group turned profitable, the standalone operations continued to incur losses. The standalone entity reported a net loss after tax of ₹88.57 lakh for the quarter, compared to a loss of ₹119.73 lakh in Q1FY25. Standalone revenue was negligible at ₹10 lakh, suggesting that the majority of the operational activity and profitability is generated through subsidiaries or associates included in the consolidated figures.

The basic earnings per share (EPS) for the consolidated entity stood at ₹0.08, compared to a negative EPS of ₹0.53 in the previous year. Paid-up equity share capital remained unchanged at ₹4,802.19 lakh.

What the Numbers Show

The divergence between consolidated and standalone results highlights the company's reliance on its group structure for current profitability. With standalone revenue at just ₹10 lakh against consolidated revenue of nearly ₹3,000 lakh, the parent entity contributes minimally to the top line. The substantial increase in consolidated revenue suggests either new business acquisitions, increased volume in subsidiary operations, or a change in consolidation scope, although the specific drivers were not detailed in the filing.